SCHEMBL16798345

SCHEMBL16798345

[CH2]C(OC)c1ccc(OC)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA12 O43570 1/20 0.52
CA14 Q9ULX7 1/20 0.52
TDP1 Q9NUW8 4/20 0.48
MAPK1 P28482 3/20 0.48
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TSHR P16473 1/20 0.48
SLC2A1 P11166 1/20 0.45
AOC3 Q16853 3/20 0.44
ACHE P22303 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
ACP3 P15309 1/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446439 0.80 CA1 (0.58) CA1CA2CA7CA9CA12
SCHEMBL6023939 0.78 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL3628156 0.78 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL10813004 0.78 CHRNA7 (0.41) CA1CA2CA7CA9TDP1
SCHEMBL3350076 0.76 CYP1A2 (0.53) CA1CA2CA7CA9CA12
SCHEMBL788402 0.76 CA12 (0.52) CA1CA2CA7CA9CA12
SCHEMBL28835630 0.76 TDP1 (0.42) TDP1MAPK1ALDH1A1L3MBTL1TSHR
SCHEMBL16798444 0.76 SLC6A4 (0.48) TDP1MAPK1TSHRAOC3LMNA
SCHEMBL27898400 0.76 CYP1A2 (0.53) CA1CA2CA7CA9CA12
SCHEMBL4196376 0.76 AOC3 (0.44) MAPK1ALDH1A1TSHRAOC3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO claimed
US-11376260-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2022-07-05 US disclosed
US-20210106593-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2021-04-15 US disclosed
US-10842799-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2020-11-24 US disclosed
US-20200078371-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2020-03-12 US disclosed
US-20190192534-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2019-06-27 US disclosed
US-10278975-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2019-05-07 US disclosed
EP-3077401-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-04-18 EP disclosed
US-20180000833-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2018-01-04 US disclosed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US disclosed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP disclosed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US disclosed
EP-3077401-A1 SERINE/THREONINE KINASE INHIBITORS Genentech, Inc. (US) 2016-10-12 EP disclosed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO disclosed
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-02 US disclosed
WO-2015085007-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376260-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-10842799-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-20150182537-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-20180000833-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-10278975-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K CA1 801/4885CA2 1246/4885CA7 2252/4885
US-20190192534-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-20210106593-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885
US-20200078371-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 CA1 4774/4885CA2 4076/4885CA7 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.